Does Medicare cover Zepbound? Yes, in two situations. Part D plans can cover Zepbound for moderate to severe obstructive sleep apnea, and since July 1, 2026, the temporary Medicare GLP-1 Bridge covers the Zepbound KwikPen for weight management at $50 a month for eligible Part D members, through December 31, 2027.[1][3] Outside those routes, Part D still excludes drugs used only for weight loss.[5]
Prices and program terms checked October 2026. They change often; confirm with the manufacturer or your plan.
Zepbound is tirzepatide; see our tirzepatide profile.
Medicare coverage of Zepbound at a glance
| Reason prescribed | Medicare route | What you pay |
|---|---|---|
| Weight management | Medicare GLP-1 Bridge (KwikPen only)[2] | $50 a month[1] |
| Moderate to severe obstructive sleep apnea | Your Part D plan[3] | Your plan’s cost-sharing |
| Type 2 diabetes | Mounjaro through your Part D plan[11] | About 8 in 10 pay $0 to $50[11] |
Why Part D excludes weight-loss drugs
Federal law bars Medicare Part D from covering drugs when used for weight loss. Plans can, however, cover the same drugs for other medically accepted uses.[5] That is why Part D plans could add Wegovy after it gained a heart-risk indication in 2024, and why Zepbound’s sleep apnea approval opened a Part D route.[5][3]
Zepbound for sleep apnea under Part D
Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.[9] CMS says beneficiaries prescribed Zepbound for this use should keep getting coverage through Medicare Part D, and plans must follow their usual formulary exception processes.[3]
What that means for you:
- Your Part D plan decides whether Zepbound is on its formulary, its tier, and its prior authorization criteria (usually a sleep study and BMI).
- Your plan’s normal deductible and copay or coinsurance apply, along with the Part D out-of-pocket cap.
- If your plan does not list Zepbound, your prescriber can ask for a formulary exception.
People with an OSA diagnosis are not eligible for the GLP-1 Bridge. A Bridge prior authorization that attests to OSA, type 2 diabetes or qualifying liver disease is denied, because those uses belong in Part D.[3] See Zepbound for sleep apnea.
The Medicare GLP-1 Bridge (weight management)
CMS launched the Bridge on July 1, 2026.[4] It works outside the normal Part D benefit, through a central processor run for CMS, and Part D plans do not need to opt in.[1]
Covered products: Wegovy (injection and tablets), Foundayo, and the Zepbound KwikPen only. Zepbound single-dose vials and single-dose pens are not covered, and pen needles are not covered.[2]
Who qualifies: adults 18 and older, prescribed the drug to reduce excess weight and keep it off along with diet and activity changes, who meet one of these at the start of GLP-1 treatment:[2]
| BMI | Plus one of |
|---|---|
| 35 or more | Nothing else needed |
| 30 or more | Heart failure with preserved ejection fraction; uncontrolled high blood pressure (above 140/90 despite two medicines); or chronic kidney disease stage 3a or worse |
| 27 or more | Prediabetes; prior heart attack; prior stroke; or symptomatic peripheral artery disease |
- People who already received a GLP-1 through their Part D plan in 2026.
- People with type 2 diabetes, obstructive sleep apnea or qualifying MASH liver disease (they use Part D).
- People in private fee-for-service, cost, PACE and some other plan types, unless they also have a standalone Part D plan.
Cost rules: you pay a flat $50 copay per 28- or 30-day fill, whatever Part D phase you are in. The Part D deductible does not apply, but no part of the $50 counts toward your true out-of-pocket costs, Extra Help does not reduce it, and it cannot be spread through the Medicare Prescription Payment Plan.[1][3] Fills of 60 or 90 days are not allowed.[2]
How to get it: your prescriber sends the prescription to a pharmacy first. The pharmacy submits the claim, and if prior authorization is needed, the request goes to the Bridge processor, usually within 24 to 72 hours. There is no formal appeal, but prescribers can resubmit.[2] Beneficiaries can find details at Medicare.gov/glp1bridge or call 1-800-MEDICARE.[1]
How the 2025-2026 changes came about
- November 6, 2025: Lilly announced an agreement with the U.S. government under which Medicare beneficiaries would pay no more than $50 a month for Zepbound in a multi-dose pen.[7]
- Net price: manufacturers agreed to supply eligible GLP-1s under the Bridge at a net price of $245 a month, according to KFF.[6]
- July 1, 2026: CMS launched the Bridge.[4]
- BALANCE model: CMS had planned a longer-term model for Part D in 2027, but on April 21, 2026, it said it would not implement BALANCE in Medicare in 2027, and the Bridge was extended through December 31, 2027. KFF notes it is unclear what happens in 2028.[6]
- Drug price negotiation: semaglutide (Ozempic, Wegovy, Rybelsus) is among the drugs with Medicare negotiated prices taking effect January 1, 2027. Tirzepatide is not on the 2026 or 2027 negotiation lists.[8]
Three common Medicare situations
You have a BMI of 37 and no diabetes or sleep apnea. You may qualify for the Bridge on BMI alone. Your prescriber sends a KwikPen prescription, the pharmacy submits it, and if approved you pay $50 per fill.[2]
You have sleep apnea and obesity. You are routed to your Part D plan, not the Bridge. Coverage and cost follow your plan’s formulary and prior authorization rules.[3]
You started Zepbound through your Part D plan earlier in 2026 for sleep apnea. You cannot switch to the Bridge for weight management in 2026; CMS says people who already received a GLP-1 through Part D that year are not eligible.[3]
Savings cards and self-pay on Medicare
Lilly’s Zepbound savings card excludes anyone enrolled in Medicare, Part D or Medicare Advantage.[10] If you do not qualify for Part D coverage or the Bridge, you can still buy Zepbound vials or the KwikPen at self-pay prices of $299 to $449 a month through LillyDirect, without billing Medicare. See Zepbound cost without insurance.
How to check your Medicare coverage
- For sleep apnea: look up Zepbound in your Part D plan’s formulary on Medicare.gov’s plan finder or your plan’s website, and ask about prior authorization.
- For weight management: check eligibility at Medicare.gov/glp1bridge and ask your prescriber to send a KwikPen prescription.[1]
- For diabetes: ask about Mounjaro on your Part D plan.[11]
- During open enrollment (October 15 to December 7), compare plans for 2027 if your current plan does not cover Zepbound for sleep apnea.
For employer and private coverage, see does insurance cover Zepbound? and our tirzepatide cost guide.
